Exciting Treatment Advances in Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Substantial developments are under way in the treatment of upper tract urothelial cancer (UTUC). Seth P. Lerner, MD, FACS, recently spoke with i3 Health about mitomycin gel (JelmytoTM, UroGen Pharma), now FDA approved as the first agent specifically indicated for the treatment of low-grade UTUC. In this second installment of his interview, Dr. Lerner, principal investigator of the OLYMPUS study, on which the mitomycin gel approval was based, discusses research advances in the treatment of both l...
Continue reading

Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer: Seth P. Lerner, MD, FACS

Upper-tract urothelial cancer (UTUC) is a rare cancer that often needs to be treated with radical surgery, typically entailing complete removal of the affected kidney, ureter, and bladder cuff. Mitomycin C formulated with a reverse thermal hydrogel (JelmytoTM, UroGen Pharma), recently approved by the FDA as the first agent specifically indicated for the treatment of low-grade UTUC, will now allow some patients to keep a kidney that would otherwise have needed to be removed. In this interview wit...
Continue reading

Mitomycin C Hydrogel Approved: Low-Grade Upper Tract Urothelial Cancer

The FDA has now approved mitomycin C formulated with a reverse thermal hydrogel (JelmytoTM, UroGen Pharma) for the treatment of adults with low-grade upper tract urothelial cancer (UTUC). Accounting for 5% to 10% of all urothelial cancers, UTUC is a rare disease; low-grade UTUC occurs at an incidence of 6,000 to 8,000 cases per year in the United States. Mitomycin C hydrogel, the first drug to be approved specifically for low-grade UTUC, is an alkylating agent, a drug that halts protei...
Continue reading

Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: Alison Birtle, MD

Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a mortality rate of over 50% for locally advanced disease. However, few clinical trials have been conducted due to its low incidence rate. Nephroureterectomy—a surgical procedure in which the renal pelvis, kidney, ureter, and bladder cuff are removed—is considered the standard treatment approach for patients with UTUC, but little research had been conducted regarding the optimal treatment after surgery. In the phase 3 PO...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.